Blockade pf CD73/adenosine axis improves the therapeutic efficacy of docetaxel in epithelial ovarian cancer
ConclusionBlocking CD73/adenosine pathway could reverse the immunosuppression caused by DTXL, and a combination of DTXL with CD73 inhibitor or anti-CD73 antibody would be a more effective and promising therapy for EOC.
Source: Archives of Gynecology and Obstetrics - Category: OBGYN Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Environmental Health | Epithelial Cancer | Immunotherapy | OBGYN | Ovarian Cancer | Ovaries | Study | Taxotere | Women